[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"New Valley University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":225},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,42,63,83,103,121,145,166,181,202],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100651302","thrombocytopenia-trajectories-in-antiphospholipid-syndrome-a-multicenter-cohort-study-100651302",false,"NCT07757789","Thrombocytopenia Trajectories in Antiphospholipid Syndrome: A Multicenter Cohort Study","Thrombocytopenia Trajectories as a Dynamic Biomarker of Clinical Severity and Survival in Antiphospholipid Syndrome: A Multicenter Cohort Study","Inclusion Criteria:\n\n* Age ≥18 years.\n* Definite APS by Sydney criteria (thrombotic and\u002For obstetric) with persistent aPL positivity.\n* ≥3 documented platelet counts over ≥12 months before inclusion (to allow trajectory modeling)\n\nExclusion Criteria:\n\n* Thrombocytopenia clearly attributable to non APS causes (e.g., chemotherapy, myelodysplastic syndromes, cirrhosis, HIV).\n* Concomitant conditions strongly affecting survival independent of APS (e.g., metastatic cancer), at investigator discretion","ALL","18 Years",{"count":19,"type":20},200,"ESTIMATED","INTERVENTIONAL",[23],"NA","Thrombocytopenia is common in antiphospholipid syndrome (APS) and is now included in the 2023 ACR\u002FEULAR APS criteria as an important non criteria\u002Fhematologic feature. Persistent or low-moderate thrombocytopenia independently predicts reduced long-term survival in APS, with hazard ratios for mortality around 2.7-4.4, and is associated with a severe disease phenotype and thrombotic deaths.",[26],"Antiphospholipid Syndrome",[28],"thrombocytopenia","RECRUITING","2026-08-05",{"date":32,"type":33},"2026-08-11","ACTUAL",{"date":35,"type":33},"2026-07-01",{"date":37,"type":20},"2027-12-31",{"name":39,"class":40},"New Valley University","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":21,"phases":50,"briefSummary":51,"conditions":52,"keywords":54,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":41},"100650095","autoimmune-hemolytic-anemia-and-its-clinical-implication-on-antiphospholipid-syndrome-100650095","NCT07743242","Autoimmune Hemolytic Anemia and Its Clinical Implication on Antiphospholipid Syndrome","Inclusion Criteria:\n\n* Adults aged ≥18 years\n* Patients with anemia consistant with hemolysis.\n* Patient diagnosed with antiphospholipid syndrome.\n* Informed consent obtained\n\nExclusion Criteria:\n\n* Age less than 18 years.\n* Other causes of anemia than autoimmune hemolysis.",{"count":49,"type":20},230,[23],"AIHA is a heterogeneous autoimmune cytopenia with variable severity and significant morbidity. APS is defined by thrombosis and\u002For obstetric morbidity with persistent antiphospholipid antibodies (aPL).",[53],"Anti Phospholipid Syndrome",[55],"AIHA",{"date":57,"type":33},"2026-08-10",{"date":59,"type":33},"2026-06-05",{"date":61,"type":20},"2028-04-15",{"name":39,"class":40},{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":4,"eligibilityCriteria":69,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":70,"targetDuration":4,"studyType":72,"phases":4,"briefSummary":73,"conditions":74,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":41},"100603878","hematological-markers-mpv-plr-and-nlr-in-primary-versus-secondary-antiphospholipid-syndrome-100603878","NCT07142239","Hematological Markers MPV, PLR, and NLR in Primary Versus Secondary Antiphospholipid Syndrome","Comparative Analysis of Hematological Markers MPV, PLR, and NLR in Primary Versus Secondary Antiphospholipid Syndrome","Inclusion Criteria:\n\n* Adults (age ≥18 years)\n* Diagnosis of APS based on updated Sydney classification criteria confirmed by: Clinical history of thrombosis and\u002For pregnancy morbidity, Persistent presence (≥12 weeks) of antiphospholipid antibodies (aCL, anti-β2-glycoprotein I, and\u002For lupus anticoagulant)\n\nExclusion criteria:\n\n* Current infection or inflammatory condition unrelated to APS\n* Hematological malignancies or other blood disorders\n* Recent blood transfusion or platelet-altering medications other than APS treatments",{"count":71,"type":20},150,"OBSERVATIONAL","Antiphospholipid syndrome is a thrombo-inflammatory autoimmune disorder with a complex antiphospholipid antibody-mediated pathogenesis, and high heterogeneity in clinical presentation and disease course. Clinical presentation in antiphospholipid syndrome includes venous and arterial thrombosis, pregnancy complications, and a broad range of microvascular and non-thrombotic manifestations",[26],"2026-07-30",{"date":77,"type":33},"2026-07-31",{"date":79,"type":33},"2025-11-27",{"date":81,"type":20},"2027-06-30",{"name":39,"class":40},{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":21,"phases":92,"briefSummary":93,"conditions":94,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":41},"100545880","characterizing-diversity-and-antifungal-resistance-in-immunocompromised-icu-patients-with-respiratory-tract-infections-100545880","NCT06387667","Characterizing Diversity and Antifungal Resistance in Immunocompromised ICU Patients With Respiratory Tract Infections","Unveiling the Fungal Frontier: Characterizing Diversity and Antifungal Resistance in Immunocompromised ICU Patients With Respiratory Tract Infections","Inclusion Criteria:\n\n* All adult patients (aged \\>18 years old) admitted to the Assiut University Hospital's intensive care units with pneumonia and hospitalized patients who developed hospital-acquired or ventilator-associated pneumonia who don't respond to antibiotics for 48 hours or with a CT finding suspected for fungal pneumonia.\n\nPatients included must have at least one of the following conditions as a contributor to immunocompromise:\n\n* Pre-existing lung disease: IPF, COPD, or sarcoidosis.\n* Immunosuppression: Neutropenia, on corticosteroids, or immunosuppressive drugs, inherited or acquired immunodeficiency.\n* Underlying comorbidities: (Diabetes Mellitus,Chronic kidney disease, Liver cirrhosis)\n* Malignancy (Hematological or solid)\n\nExclusion Criteria:\n\n* Patients refused to contribute to the study.\n* Unsatisfactory sample.",{"count":91,"type":20},250,[23],"Immunocompromised individuals face a heightened risk of life-threatening fungal infections, which arise from a multitude of environmental and commensal fungi. Surveillance data from ICUs worldwide identifies Candida spp. as the dominant foe, responsible for 80% of such infections, earning it the dubious distinction of being the third most prevalent pathogen. While C. albicans holds the dubious crown as the most common Candida offender, recent years have witnessed a concerning trend toward non-Albicans candida, raising concerns about potential antifungal resistance.",[95],"Immunocompromised ICU Patients With Respiratory Tract Infections","2026-07-29",{"date":75,"type":33},{"date":99,"type":33},"2025-12-01",{"date":101,"type":20},"2027-06-01",{"name":39,"class":40},{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":109,"sex":16,"minAge":110,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":72,"phases":4,"briefSummary":112,"conditions":113,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":115,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":41},"100521269","relationship-between-red-cell-distribution-width-rdw-and-hba1c-in-patients-with-type-2-diabetes-mellitus-after-glycemic-control-100521269","NCT06067399","Relationship Between Red Cell Distribution Width (RDW) and HbA1C in Patients With Type 2 Diabetes Mellitus After Glycemic Control","Inclusion Criteria:\n\n* Patients diagnosed to have Uncontrolled type 2 diabetes mellitus (HbA1C more than 7%)\n\nExclusion Criteria:\n\n1. Patients diagnosed to have type 1 diabetes.\n2. Patients are diagnosed to have secondary diabetes.\n3. Clinical states associated with increased RDW:\n\n   * Anemia (Female Hb less than 12, Male Hb less than 13) either due to hemolysis, or in response to ineffective red cell production, which can be caused by deficiencies in iron, vitamin B12 or folate.\n   * After blood transfusions\n   * Pregnancy, thrombotic thrombocytopenic purpura and inflammatory bowel disease.",true,"40 Years",{"count":91,"type":20},"Diabetes mellitus (DM) is an epidemic disease, with approximately 463 million persons diagnosed with it. Of those, 90% are patients with type 2 DM (T2DM). Some estimates indicate that 700 million cases of DM will be reported in 2045. T2DM develops due to insulin resistance, leading to reduced insulin secretion. DM has a number of associated complications, such as nephropathy, neuropathy, and cardiovascular disease.",[114],"Type 2 Diabetes",{"date":75,"type":33},{"date":117,"type":33},"2026-05-01",{"date":119,"type":20},"2028-06-30",{"name":39,"class":40},{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":128,"enrollmentInfo":129,"targetDuration":4,"studyType":21,"phases":131,"briefSummary":134,"conditions":135,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":41},"100553795","phase-1-effects-of-dexmedetomidine-versus-ketamine-on-inflammatory-response-and-hemodynamic-in-patients-100553795","NCT06490731","Effects of Dexmedetomidine Versus Ketamine on Inflammatory Response and Hemodynamic in Patients","Effects of Dexmedetomidine Versus Ketamine on Inflammatory Response and Hemodynamic in Patients With Intraabdominal Sepsis: A Randomized Controlled Study","Inclusion Criteria:\n\n* • Adult patients admitted to ICU after ileus surgery (perforated viscus, infarcted bowel, strangulated hernia, anastomotic leakage, diverticulitis, and intestinal obstruction), and who will be expected to require postoperative sedation and ventilation.\n\n  * Abdominal sepsis was determined as organ dysfunction with a substantial change in overall SOFA score (2) ≥ 2 points because of intra-abdominal sepsis.\n\nExclusion Criteria:\n\n* • Known allergy to ketamine, dexmedetomidine,\n\n  * Confirmed pregnancy,\n  * Heart failure (class 3 or 4 of the New York Heart Association),\n  * Renal failure (RIFLE classification),\n  * Liver failure (manifested by serum total protein concentration \\\u003C3 g\u002Fdl and total bilirubin \\>5 mg\u002Fdl)\n  * Known or suspected brain death.\n  * Patients who receive neuromuscular blockers during the first 48 hours of ICU admission will also be excluded.","70 Years",{"count":130,"type":20},2,[132,133],"PHASE1","PHASE2","Inflammatory response and hemodynamic response in patients with intraabdominal sepsis and Effects of Dexmedetomidine versus ketamine on it .",[136],"Haemodynamic Rebound","2026-05-02",{"date":139,"type":33},"2026-05-07",{"date":141,"type":33},"2026-04-01",{"date":143,"type":20},"2026-10-01",{"name":39,"class":40},{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":16,"minAge":152,"maxAge":153,"enrollmentInfo":154,"targetDuration":4,"studyType":21,"phases":156,"briefSummary":157,"conditions":158,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":160,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":41},"100547341","retroclavicular-block-in-vascular-surgey-100547341","NCT06406712","Retroclavicular Block in Vascular Surgey","Efficacy of Retroclavicular Dexamethasone With Bupivacaine in Patients Undergoing Upper Limb Vascular Surgeries","Inclusion Criteria:\n\n* Patients undergoing upper limb vascular surgey .\n\nExclusion Criteria:\n\n* \\- Contraindications to regional block (coagulopathy, infection at the needle insertion site, or diaphragmatic paralysis).\n* Altered conscious level.\n* Pregnancy.\n* Body mass index (BMI \\> 35).\n* Patients who have difficulty understanding the study protocol.\n* Patients who have any known contraindication to study medications.\n* Patient refusal.","20 Years","65 Years",{"count":155,"type":20},80,[23],"The retroclavicular (coracoid) approach for brachial plexus anesthesia is recognized for its facility and simplicity to perform .\n\nThe block has been well described in the anesthesia community since it was first introduced by Hebbard and Royse in 2007 . In 2017, Luftig . first described the block's use in the ED setting for a variety of indications . Because of its different needle entry point, the retro clavicular (RCB) approach offers an almost perpendicular needle-ultrasound (US) beam angle.",[159],"Pain Management",{"date":139,"type":33},{"date":162,"type":33},"2024-06-01",{"date":164,"type":20},"2026-12-01",{"name":39,"class":40},{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":4,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":16,"minAge":152,"maxAge":153,"enrollmentInfo":173,"targetDuration":4,"studyType":21,"phases":174,"briefSummary":175,"conditions":176,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":177,"startDateStruct":178,"completionDateStruct":179,"leadSponsor":180,"locationsCount":41},"100547336","rectroclavicular-block-in-orthopedic-surgey-100547336","NCT06406647","Rectroclavicular Block in Orthopedic Surgey","Adding Ketamine as Adjuvant in Retroclavicular Block in Upper Limb Orthopedic Surgey","Inclusion Criteria:\n\n* Patients undergoing upper limb orthopedic surgery,\n\nExclusion Criteria:\n\n* \\- Contraindications to regional block (coagulopathy, infection at the needle insertion site, or diaphragmatic paralysis).\n* Altered conscious level.\n* Pregnancy.\n* Body mass index (BMI \\> 35).\n* Patients who have difficulty understanding the study protocol.\n* Patients who have any known contraindication to study medications.\n* Patient refusal.",{"count":155,"type":20},[23],"The ultrasound-guided retroclavicular approach to the infraclavicular region (RAPTIR) brachial plexus block has gained popularity as a relatively easy-to-perform nerve block that provides reliable and dense anesthesia to the upper extremity with a single injection. The block has been well described in the anesthesia community since it was first introduced by Hebbard and Royse in 2007 . In 2017, Luftig first described the block's use in the ED setting for a variety of indications . This nerve block has classically been described to provide extensive anesthesia for procedures distal to the shoulder, such as elbow dislocations, distal radius fractures, and surgical procedures.",[159],{"date":139,"type":33},{"date":141,"type":33},{"date":164,"type":20},{"name":39,"class":40},{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":188,"targetDuration":4,"studyType":72,"phases":4,"briefSummary":190,"conditions":191,"keywords":4,"overallStatus":193,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":4},"100606130","correlation-between-oct-and-mf-erg-findings-with-bcva-in-patients-with-macular-dystrophy-100606130","NCT07171541","Correlation Between OCT and Mf-ERG Findings With BCVA in Patients With Macular Dystrophy","Correlation Between Optical Coherence Tomography and Multifocal Electroretinogram Findings With Visual Acuity in Patients With Macular Dystrophy","Inclusion Criteria:\n\n* All patients diagnosed with macular dystrophy in Tiba Eye Centre, Egypt, Assiut, during the period of the study\n\nExclusion Criteria:\n\n* The patients diagnosed with macular dystrophy refuse to contribute to the study.",{"count":189,"type":20},30,"Correlation between optical coherence tomography and multifocal electroretinogram findings with visual acuity in patients with macular dystrophy.",[192],"Macular Dystrophy","NOT_YET_RECRUITING","2025-09-08",{"date":196,"type":33},"2025-09-12",{"date":198,"type":20},"2025-09-20",{"date":200,"type":20},"2025-12-20",{"name":39,"class":40},{"id":203,"slug":204,"hasResults":11,"nctId":205,"briefTitle":206,"officialTitle":206,"acronym":4,"eligibilityCriteria":207,"healthyVolunteers":11,"sex":208,"minAge":17,"maxAge":4,"enrollmentInfo":209,"targetDuration":4,"studyType":21,"phases":211,"briefSummary":212,"conditions":213,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":222,"leadSponsor":224,"locationsCount":41},"100569658","can-cox-2-inhibitor-decrease-stricture-recurrence-after-direct-vision-internal-urethrotomy-100569658","NCT06697106","Can COX-2 Inhibitor Decrease Stricture Recurrence After Direct Vision Internal Urethrotomy?","Inclusion Criteria:\n\n* Age ≥ 18 years\n* American Society of Anesthesiologists (ASA) score ≤3.\n* Urethral stricture length ≤ 1.5 cm\n\nExclusion Criteria:\n\n* Recurrent urethral stricture ≥ 2 times.\n* Pelvic fracture urethral distraction defect (PFUDD).","MALE",{"count":210,"type":20},82,[23],"To evaluate the efficacy and safety of nonsteroidal anti-inflammatory drugs (NSAIDs) in preventing urethral stricture recurrence after direct visual internal urethrotomy.",[214,215,216,217],"COX-2 Inhibitor","Meloxicam","Stricture Recurrence","Direct Vision Internal Urethrotomy","2024-11-20",{"date":220,"type":33},"2024-11-21",{"date":218,"type":33},{"date":223,"type":20},"2025-04-01",{"name":39,"class":40},""]